Brinzolamide API Powder CAS 138890-62-7

Brinzolamide API powder CAS 138890-62-7 is a novel topical heterocyclic sulfonamide carbonic anhydrase inhibitor with strong affinity and inhibitory activity against carbonic anhydrase isoenzyme II (CAII) in the human ciliary body. It selectively, with high affinity and significant inhibition of CAII activity, effectively lowering intraocular pressure (IOP) with the advantages of high efficacy, low toxicity, and minimal side effects.

Carbonic anhydrase (CA) is one of the main protein components of red blood cells, second only to hemoglobin, and is present in many body tissues, including the eye. CA catalyzes the reversible reaction of carbon dioxide hydration to carbonic acid and carbonic acid dehydration. Inhibiting carbonic anhydrase in the ciliary body reduces aqueous humor secretion, possibly by reducing bicarbonate ion production, thereby decreasing sodium and water transport and ultimately lowering IOP. IOP is a significant risk factor for optic nerve damage and glaucomatous visual field defects caused by glaucomatous optic nerve damage. Brinzolamide primarily inhibits the dominant carbonic anhydrase type 2 isoenzyme in ocular tissues. In in vitro experiments, the 50% effective inhibitory concentration was 3.2 nM, and the Ki value for carbonic anhydrase type 2 isoenzyme was 0.13 nM.